Pakistan Takes 'Emergency' Steps To Secure Drugs After India Trade Halt Post Pahalgam Terror Attack: Report
The Drug Regulatory Authority of Pakistan (DRAP) has confirmed that contingency plans are in place, though no formal notification has yet been issued regarding the ban's impact on the pharmaceutical sector. DRAP officials stated that preparations for such disruptions began after the 2019 crisis, and they are now actively seeking alternative sources from China, Russia, and several European nations in order to maintain the supply of essential medicines, such as anti-rabies vaccines, anti-snake venom, cancer therapies, and monoclonal antibodies.
Also Read | Akshay Kumar surprises audience at Kesari 2 show, talk on Pahalgam terror attackDespite these efforts, industry insiders and health experts warn of significant challenges ahead if immediate action is not taken. The Ministry of Health has yet to receive an official directive clarifying the status of pharmaceutical imports, and there are growing fears of critical shortages within the sector. The situation is further complicated by a thriving black market, where unregistered and unapproved medicines-often of Indian origin-are smuggled into Pakistan via Afghanistan, Iran, Dubai, and across the eastern border. While these illicit channels fill gaps left by legal imports, they provide no assurance of quality or reliability.
In response, a delegation from the Pakistan Pharmaceutical Manufacturers Association (PPMA) has appealed to authorities in Islamabad for an exemption from the trade ban, arguing that many life-saving products depend exclusively on Indian raw materials. The PPMA has also approached the Special Investment Facilitation Council (SIFC), urging that pharmaceutical and health-related trade be excluded from the ban to protect patients' lives.
Also Read | Pak army chief Gen Munir reiterates 'two-nation' theory after Pahalgam attackSome experts suggest that this crisis could serve as a catalyst for Pakistan to invest in domestic production of APIs, vaccines, and biologicals, thereby reducing future reliance on foreign suppliers.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment